WCN26-5800 VISOR: AN ONGOING REPEAT-BIOPSY CLINICAL TRIAL ASSESSING CHANGES IN KIDNEY HISTOLOGY IN PEOPLE WITH IgA NEPHROPATHY TREATED WITH SIBEPRENLIMAB

Read full text Summarise with VIRAT
Authors: Chee Kay Cheung, Jonathan Barratt, Ian S D Roberts, Meghan E. Sise, Michael Walsh, H. Trimarchi, Alejandra Smuclir Quevedo, Yusuke Suzuki, Hitoshi Suzuki, Laura Ann Kooienga, Jeffrey Hafkin, Gerard Honig
+2 more Lokesh N. Shah, Dana V. Rizk
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

A proliferation-inducing ligand (APRIL) plays a key role in the pathogenesis of immunoglobulin A (IgA) nephropathy, a progressive immune-mediated chronic kidney disease characterized by the deposition of Gd-IgA1–containing immune complexes in the glomerular mesangium. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and blocks the biological actions of APRIL. In the Phase 2 ENVISION trial (NCT04287985), sibeprenlimab reduced proteinuria, stabilized eGFR, suppressed serum APRIL, and decreased Gd-IgA1 levels in people with IgA nephropathy.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106253–106253
Publication date
25 March 2026
Language
EN